Crestor is off and running in U.S. statin market

10/3/2003 | Philadelphia Inquirer, The

AstraZeneca's new cholesterol-lowering drug, Crestor, is winning more than 2% of new prescriptions since its U.S. launch last month. Already available in much of Europe and Canada, Crestor could generate peak sales of more than $3 billion and capture 20% of the global market for cholesterol drugs. It's in fierce competition with Pfizer's Lipitor, the world's top selling medicine.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC